Literature DB >> 26386029

Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.

Jose F Camargo1, Jacques Simkins2, Thiago Beduschi3, Akin Tekin3, Laura Aragon4, Armando Pérez-Cardona5, Clara E Prado6, Michele I Morris2, Lilian M Abbo2, Rafael Cantón7.   

Abstract

New antibiotic options are urgently needed for the treatment of carbapenem-resistant Enterobacteriaceae infections. We report a 64-year-old female with prolonged hospitalization following an intestinal transplant who developed refractory bacteremia due to a serine carbapenemase-producing pandrug-resistant isolate of Klebsiella pneumoniae. After failing multiple antimicrobial regimens, the patient was successfully treated.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26386029      PMCID： PMC4576028          DOI： 10.1128/AAC.00655-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.

Authors:  J Kohler; K L Dorso; K Young; G G Hammond; H Rosen; H Kropp; L L Silver
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 3.  The pharmacokinetic and pharmacodynamic profile of tigecycline.

Authors:  Alison K Meagher; Paul G Ambrose; Thaddeus H Grasela; Evelyn J Ellis-Grosse
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

Review 4.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

5.  Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients.

Authors:  Jason A Roberts; Carl M J Kirkpatrick; Jeffrey Lipman
Journal:  J Antimicrob Chemother       Date:  2010-11-30       Impact factor: 5.790

6.  Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.

Authors:  Alessandra Oliva; Maria T Mascellino; Alessia Cipolla; Alessandra D'Abramo; Annalisa De Rosa; Stefano Savinelli; Maria Rosa Ciardi; Claudio M Mastroianni; Vincenzo Vullo
Journal:  Int J Infect Dis       Date:  2015-01-15       Impact factor: 3.623

7.  Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model.

Authors:  G L Daikos; A Panagiotakopoulou; E Tzelepi; A Loli; L S Tzouvelekis; V Miriagou
Journal:  Clin Microbiol Infect       Date:  2007-02       Impact factor: 8.067

Review 8.  Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?

Authors:  Rafael Cantón; Andrés Canut; María Isabel Morosini; Antonio Oliver
Journal:  Enferm Infecc Microbiol Clin       Date:  2014-12       Impact factor: 1.731

9.  Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Elizabeth A Neuner; Jun-Yen Yeh; Gerri S Hall; Jennifer Sekeres; Andrea Endimiani; Robert A Bonomo; Nabin K Shrestha; Thomas G Fraser; David van Duin
Journal:  Diagn Microbiol Infect Dis       Date:  2011-04       Impact factor: 2.803

10.  Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  M V Hayes; D C Orr
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790
View more
  18 in total

1.  Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Authors:  Krystyna M Kazmierczak; Douglas J Biedenbach; Meredith Hackel; Sharon Rabine; Boudewijn L M de Jonge; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  Nosocomial, Multidrug-Resistant Klebsiella pneumoniae Strains Isolated from Mexico City Produce Robust Biofilms on Abiotic Surfaces but Not on Human Lung Cells.

Authors:  Martha Lorena Ostria-Hernandez; Karla Cecilia Juárez-de la Rosa; Patricia Arzate-Barbosa; Antonino Lara-Hernández; Fuminori Sakai; J Antonio Ibarra; Graciela Castro-Escarpulli; Jorge E Vidal
Journal:  Microb Drug Resist       Date:  2017-09-15       Impact factor: 3.431

3.  Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.

Authors:  M Souli; I Karaiskos; A Masgala; L Galani; E Barmpouti; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-16       Impact factor: 3.267

4.  Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.

Authors:  Elizabeth Temkin; Julian Torre-Cisneros; Bojana Beovic; Natividad Benito; Maddalena Giannella; Raúl Gilarranz; Cameron Jeremiah; Belén Loeches; Isabel Machuca; María José Jiménez-Martín; José Antonio Martínez; Marta Mora-Rillo; Enrique Navas; Michael Osthoff; Juan Carlos Pozo; Juan Carlos Ramos Ramos; Marina Rodriguez; Miguel Sánchez-García; Pierluigi Viale; Michel Wolff; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 5.  Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles.

Authors:  Olivia Smibert; Michael J Satlin; Anoma Nellore; Anton Y Peleg
Journal:  Curr Infect Dis Rep       Date:  2019-06-10       Impact factor: 3.725

6.  A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam.

Authors:  Alessandra Iacovelli; Martina Spaziante; Samir Al Moghazi; Alessandra Giordano; Giancarlo Ceccarelli; Mario Venditti
Journal:  Infection       Date:  2018-06-20       Impact factor: 3.553

7.  "Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by blaNDM -harboring Enterobacteriaceae in kidney transplantation.

Authors:  Rossana Rosa; Susan D Rudin; Laura J Rojas; Andrea M Hujer; Armando Perez-Cardona; Federico Perez; Robert A Bonomo; Octavio Martinez; Lilian M Abbo; Jose F Camargo
Journal:  Transpl Infect Dis       Date:  2017-11-27       Impact factor: 2.228

8.  Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation Assays.

Authors:  Juliana Januário Gaudereto; Lauro Vieira Perdigão Neto; Gleice Cristina Leite; Roberta Ruedas Martins; Gladys Villas Boas do Prado; Flavia Rossi; Thais Guimarães; Anna Sara Levin; Silvia Figueiredo Costa
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 9.  The rapid spread of carbapenem-resistant Enterobacteriaceae.

Authors:  Robert F Potter; Alaric W D'Souza; Gautam Dantas
Journal:  Drug Resist Updat       Date:  2016-09-19       Impact factor: 18.500

10.  Modelling of the transmission dynamics of carbapenem-resistant Klebsiella pneumoniae in hospitals and design of control strategies.

Authors:  Suttikiat Changruenngam; Charin Modchang; Dominique J Bicout
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.